<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.0 20040830//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">09-PONE-RA-14140R1</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0009462</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Biochemistry/Structural Genomics</subject><subject>Genetics and Genomics/Genetics of Disease</subject><subject>Diabetes and Endocrinology/Type 2 Diabetes</subject></subj-group></article-categories><title-group><article-title>Sequence Variation in <italic>DDAH1</italic> and <italic>DDAH2</italic> Genes Is Strongly and Additively Associated with Serum ADMA Concentrations in Individuals with Type 2 Diabetes</article-title><alt-title alt-title-type="running-head"><italic>DDAH</italic> Gene Variation and ADMA</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Abhary</surname><given-names>Sotoodeh</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>&#x0002a;</sup></xref></contrib><contrib contrib-type="author"><name><surname>Burdon</surname><given-names>Kathryn P.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kuot</surname><given-names>Abraham</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Javadiyan</surname><given-names>Shahrbanou</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Whiting</surname><given-names>Malcolm J.</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kasmeridis</surname><given-names>Nicholas</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Petrovsky</surname><given-names>Nikolai</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Craig</surname><given-names>Jamie E.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>Department of Ophthalmology, Flinders Medical Centre and Flinders University, Adelaide, South Australia, Australia</addr-line></aff><aff id="aff2"><label>2</label><addr-line>Department of Endocrinology, Flinders Medical Centre and Flinders University, Adelaide, South Australia, Australia</addr-line></aff><aff id="aff3"><label>3</label><addr-line>Chemical Pathology Laboratory, SA Pathology, Adelaide, South Australia, Australia</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Maedler</surname><given-names>Kathrin</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">University of Bremen, Germany</aff><author-notes><corresp id="cor1">&#x0002a; E-mail: <email>sotoodeh.abhary@health.sa.gov.au</email></corresp><fn fn-type="con"><p>Conceived and designed the experiments: SA KB NK NP JEC. Performed the experiments: SA AK SJ MJW. Analyzed the data: SA KB SJ MJW NK NP JEC. Contributed reagents/materials/analysis tools: AK MJW JEC. Wrote the paper: SA KB AK SJ NK NP JEC.</p></fn></author-notes><pub-date pub-type="collection"><year>2010</year></pub-date><pub-date pub-type="epub"><day>1</day><month>3</month><year>2010</year></pub-date><volume>5</volume><issue>3</issue><elocation-id>e9462</elocation-id><history><date date-type="received"><day>10</day><month>11</month><year>2009</year></date><date date-type="accepted"><day>4</day><month>2</month><year>2010</year></date></history><permissions><copyright-statement>Abhary et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</copyright-statement></permissions><abstract><sec><title>Background</title><p>Asymmetric dimethylarginine (ADMA), present in human serum, is an endogenous inhibitor of nitric oxide synthase and contributes to vascular disease. Dimethylarginine dimethylaminohydrolase (DDAH) is an ADMA degrading enzyme that has two isoforms: DDAHI and DDAHII. We sought to determine whether serum ADMA levels in type 2 diabetes are influenced by common polymorphisms in the <italic>DDAH1</italic> and <italic>DDAH2</italic> genes.</p></sec><sec><title>Methodology/Principal Findings</title><p>Relevant clinical parameters were measured and peripheral whole blood obtained for serum and genetic analysis on 343 participants with type 2 diabetes. Serum ADMA concentrations were determined by mass spectroscopy. Twenty six tag SNPs in the <italic>DDAH1</italic> and 10 in the <italic>DDAH2</italic> gene were genotyped in all subjects and tested for association with serum ADMA levels. Several SNPs and haplotypes in the <italic>DDAH</italic> genes were strongly associated with ADMA levels. Most significantly in the <italic>DDAH1</italic> gene, rs669173 (p&#x0200a;&#x0003d;&#x0200a;2.96&#x000d7;10<sup>&#x02212;7</sup>), rs7521189 (p&#x0200a;&#x0003d;&#x0200a;6.40&#x000d7;10<sup>&#x02212;7</sup>), rs2474123 (p&#x0200a;&#x0003d;&#x0200a;0.00082) and rs13373844 (p&#x0200a;&#x0003d;&#x0200a;0.00027), and in the <italic>DDAH2</italic> gene, rs3131383 (p&#x0200a;&#x0003d;&#x0200a;0.0029) and the <named-content content-type="gene">TGCCCAGGAG</named-content> haplotype (p&#x0200a;&#x0003d;&#x0200a;0.0012) were significantly associated with ADMA levels. Sub-analysis by diabetic retinopathy (DR) status revealed these variants were associated with ADMA levels predominantly in participants without DR. Combined analysis of the most strongly associated SNPs in <italic>DDAH1</italic> (rs669173) and <italic>DDAH2</italic> (rs3131383) revealed an additive effect (p&#x0200a;&#x0003d;&#x0200a;1.37&#x000d7;10<sup>&#x02212;8</sup>) on ADMA levels.</p></sec><sec><title>Conclusions/Significance</title><p>Genetic variation in the <italic>DDAH1</italic> and <italic>2</italic> genes is significantly associated with serum ADMA levels. Further studies are required to determine the pathophysiological significance of elevated serum ADMA in type 2 diabetes and to better understand how <italic>DDAH</italic> gene variation influences ADMA levels.</p></sec></abstract><counts><page-count count="8"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide synthase (NOS), the key endothelial enzyme that converts L-arginine to L-citrulline and nitric oxide (NO). Endothelium-derived NO helps to maintain vascular homeostasis through vasodilatation, suppression of inflammation and inhibition of the proliferation of vascular smooth muscle cells <xref ref-type="bibr" rid="pone.0009462-Dimmeler1">&#x0005b;1&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009462-Wang1">&#x0005b;2&#x0005d;</xref>, platelet adhesion and aggregation <xref ref-type="bibr" rid="pone.0009462-Stamler1">&#x0005b;3&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009462-Oelze1">&#x0005b;4&#x0005d;</xref>.</p><p>ADMA levels have been shown to be increased in individuals with diabetes mellitus <xref ref-type="bibr" rid="pone.0009462-Abbasi1">&#x0005b;5&#x0005d;</xref>. Endothelial dysfunction, such as occurs in hyperglycemia, is associated with decreased NOS activity and NO bioavailability resulting in vasoconstriction and increased reactive oxygen species. This leads to impaired ocular hemodynamics <xref ref-type="bibr" rid="pone.0009462-Toda1">&#x0005b;6&#x0005d;</xref>. Recently, elevated serum ADMA in both diabetes <xref ref-type="bibr" rid="pone.0009462-Abbasi1">&#x0005b;5&#x0005d;</xref> and its complications, including retinopathy <xref ref-type="bibr" rid="pone.0009462-Makino1">&#x0005b;7&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009462-Malecki1">&#x0005b;8&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009462-Sugai1">&#x0005b;9&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009462-Abhary1">&#x0005b;10&#x0005d;</xref> and nephropathy <xref ref-type="bibr" rid="pone.0009462-Abhary1">&#x0005b;10&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009462-Hanai1">&#x0005b;11&#x0005d;</xref>, have been reported.</p><p>Dimethylarginine dimethylaminohydrolase (DDAH) is the enzyme responsible for the degradation of ADMA into citrulline and dimethylamine <xref ref-type="bibr" rid="pone.0009462-Achan1">&#x0005b;12&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009462-Teerlink1">&#x0005b;13&#x0005d;</xref>. Over 90&#x00025; of endogenous ADMA is metabolised by DDAH with the remainder renally excreted <xref ref-type="bibr" rid="pone.0009462-Tran1">&#x0005b;14&#x0005d;</xref>. DDAH is expressed as two isoforms encoded by different genes. DDAHI predominates in tissues expressing neuronal NOS (nNOS), and is encoded by the <italic>DDAH1</italic> (OMIM#604743) gene on chromosome 1p22. DDAHII is found in highly vascular tissues expressing endothelial NOS (eNOS) <xref ref-type="bibr" rid="pone.0009462-Leiper1">&#x0005b;15&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009462-Tran2">&#x0005b;16&#x0005d;</xref>, and immune tissues expressing inducible NOS (iNOS) <xref ref-type="bibr" rid="pone.0009462-Tran2">&#x0005b;16&#x0005d;</xref>, and is encoded by the <italic>DDAH2</italic> (OMIM#604744) gene on chromosome 6p21.3.</p><p>Evidence for the metabolic control of ADMA by DDAH genes, and their influence on endothelial cells has been provided by animal studies. <italic>DDAH1</italic> overexpressing transgenic mice had a two fold reduction in plasma ADMA associated with a 2 fold increase in tissue NOS activity <xref ref-type="bibr" rid="pone.0009462-Dayoub1">&#x0005b;17&#x0005d;</xref>. Conversely, <italic>DDAH1</italic> knockout mice had increased pulmonary endothelial permeability as a result of ADMA elevation, which was prevented by overexpression of <italic>DDAH1</italic> and <italic>DDAH2</italic> in endothelial cells <xref ref-type="bibr" rid="pone.0009462-WojciakStothard1">&#x0005b;18&#x0005d;</xref>.</p><p>We aimed to determine whether serum ADMA levels are influenced by common single nucleotide polymorphisms (SNPs) in <italic>DDAH1</italic> and <italic>DDAH2</italic> genes in a large Australian cohort of individuals with type 2 diabetes, and found that genetic variation in the <italic>DDAH1</italic> and <italic>DDAH2</italic> genes significantly and additively affects serum ADMA concentrations.</p></sec><sec id="s2"><title>Results</title><p>Three hundred and forty three participants with type 2 diabetes were included. Disease duration, smoking, nephropathy and diabetic retinopathy were significantly associated with serum ADMA levels in all participants (p&#x0003c;0.05, <xref ref-type="table" rid="pone-0009462-t001">Table 1</xref>). These variables were subsequently adjusted for in multivariate analyses. Subjects with no retinopathy (n&#x0200a;&#x0003d;&#x0200a;225) were more likely to be female, had shorter duration of disease, significantly lower HbA1c levels and less nephropathy when compared to subjects with blinding diabetic retinopathy (n&#x0200a;&#x0003d;&#x0200a;118, data not shown).</p><table-wrap id="pone-0009462-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0009462.t001</object-id><label>Table 1</label><caption><title>Clinical characteristics &#x0005b;number of subjects (&#x00025;) or mean&#x000b1;standard deviation&#x0005d; of all participants and associations with serum ADMA levels.</title></caption><alternatives><graphic id="pone-0009462-t001-1" xlink:href="pone.0009462.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Clinical characteristics</td><td align="left" rowspan="1" colspan="1">All participants (n&#x0200a;&#x0003d;&#x0200a;343)</td><td align="left" rowspan="1" colspan="1">Pearson Correlation</td><td align="left" rowspan="1" colspan="1">P value</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Female (&#x00025;)</td><td align="left" rowspan="1" colspan="1">162 (47)</td><td align="left" rowspan="1" colspan="1">&#x02212;0.054</td><td align="left" rowspan="1" colspan="1">0.316</td></tr><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="left" rowspan="1" colspan="1">63.7&#x000b1;12.9</td><td align="left" rowspan="1" colspan="1">0.006</td><td align="left" rowspan="1" colspan="1">0.914</td></tr><tr><td align="left" rowspan="1" colspan="1">Disease duration (years)</td><td align="left" rowspan="1" colspan="1">14.8&#x000b1;8.9</td><td align="left" rowspan="1" colspan="1">0.138</td><td align="left" rowspan="1" colspan="1">0.011</td></tr><tr><td align="left" rowspan="1" colspan="1">HbA1c (&#x00025;)</td><td align="left" rowspan="1" colspan="1">7.9&#x000b1;1.8</td><td align="left" rowspan="1" colspan="1">0.099</td><td align="left" rowspan="1" colspan="1">0.098</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI (kg/m2)</td><td align="left" rowspan="1" colspan="1">32.3&#x000b1;7.2</td><td align="left" rowspan="1" colspan="1">0.074</td><td align="left" rowspan="1" colspan="1">0.182</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypercholesterolemia (&#x00025;)</td><td align="left" rowspan="1" colspan="1">249 (70)</td><td align="left" rowspan="1" colspan="1">&#x02212;0.019</td><td align="left" rowspan="1" colspan="1">0.728</td></tr><tr><td align="left" rowspan="1" colspan="1">Smoker (&#x00025;)</td><td align="left" rowspan="1" colspan="1">178 (52)</td><td align="left" rowspan="1" colspan="1">0.115</td><td align="left" rowspan="1" colspan="1">0.033</td></tr><tr><td align="left" rowspan="1" colspan="1">Retinopathy (&#x00025;)</td><td align="left" rowspan="1" colspan="1">118 (35)</td><td align="left" rowspan="1" colspan="1">0.115</td><td align="left" rowspan="1" colspan="1">0.034</td></tr><tr><td align="left" rowspan="1" colspan="1">Nephropathy (&#x00025;)</td><td align="left" rowspan="1" colspan="1">95 (28)</td><td align="left" rowspan="1" colspan="1">0.111</td><td align="left" rowspan="1" colspan="1">0.041</td></tr><tr><td align="left" rowspan="1" colspan="1">GFR (mL/min)</td><td align="left" rowspan="1" colspan="1">121.5&#x000b1;407.4</td><td align="left" rowspan="1" colspan="1">0.022</td><td align="left" rowspan="1" colspan="1">0.702</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypertension (&#x00025;)</td><td align="left" rowspan="1" colspan="1">285 (83)</td><td align="left" rowspan="1" colspan="1">0.050</td><td align="left" rowspan="1" colspan="1">0.352</td></tr></tbody></table></alternatives></table-wrap><p>Several SNPs in the <italic>DDAH</italic> genes were significantly associated with serum ADMA levels after adjusting for associated variables in the multivariate analyses (<xref ref-type="table" rid="pone-0009462-t002">Table 2</xref> and <xref ref-type="fig" rid="pone-0009462-g001">Figure 1</xref>), with the most significant in <italic>DDAH1</italic> being rs669173 &#x0005b;p&#x0200a;&#x0003d;&#x0200a;2.96&#x000d7;10<sup>&#x02212;7</sup> in the genotypic model, Beta coefficient (B): &#x02212;0.03, 95&#x00025; CI: &#x02212;0.04 to &#x02212;0.02&#x0005d;, rs7521189 (p&#x0200a;&#x0003d;&#x0200a;6.40&#x000d7;10<sup>&#x02212;7</sup> in the additive model, B: &#x02212;0.03, 95&#x00025; CI: &#x02212;0.04 to &#x02212;0.01), rs2474123 (p&#x0200a;&#x0003d;&#x0200a;0.00082 in the additive model, B: 0.02, 95&#x00025;CI: 0.01&#x02013;0.04), rs13373844 (p&#x0200a;&#x0003d;&#x0200a;0.00027 in the dominant model, B: &#x02212;0.03, 95&#x00025; CI: &#x02212;0.05 to &#x02212;0.02) and rs986639 (p&#x0200a;&#x0003d;&#x0200a;0.0015 in the genotypic model, B: 0.03, 95&#x00025; CI: 0.01&#x02013;0.05). The SNPSpD method for multiple testing correction in SNP association studies estimated a total of 17 independent tests for <italic>DDAH1</italic> analyses and after correcting for multiple testing, the SNPs listed above remained significantly associated with serum ADMA levels (p&#x0003c;0.03, <xref ref-type="table" rid="pone-0009462-t002">Table 2</xref>).</p><fig id="pone-0009462-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0009462.g001</object-id><label>Figure 1</label><caption><title>Idiogram of significantly associated SNPs and haplotypes of <italic>DDAH I</italic> (1A) and <italic>DDAH</italic> II (1B) with serum ADMA levels.</title><p>Scales of genomic regions are estimates. P values are presented for significant SNPs and haplotype associations have been adjusted for disease duration, age, hypertension, smoking, nephropathy and diabetic retinopathy.</p></caption><graphic xlink:href="pone.0009462.g001"/></fig><table-wrap id="pone-0009462-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0009462.t002</object-id><label>Table 2</label><caption><title>Association of <italic>DDAH</italic> tag SNPs and with serum ADMA levels in all participants.</title></caption><alternatives><graphic id="pone-0009462-t002-2" xlink:href="pone.0009462.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Additive</td><td align="left" rowspan="1" colspan="1">Genotypic</td><td align="left" rowspan="1" colspan="1">Dominant</td><td align="left" rowspan="1" colspan="1">Recessive</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">SNP #</td><td align="left" rowspan="1" colspan="1">SNP name</td><td align="left" rowspan="1" colspan="1">Minor allele</td><td align="left" rowspan="1" colspan="1">P value</td><td align="left" rowspan="1" colspan="1">P value</td><td align="left" rowspan="1" colspan="1">P value</td><td align="left" rowspan="1" colspan="1">P value</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">DDAH1</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">rs17590006</td><td align="left" rowspan="1" colspan="1">G</td><td align="left" rowspan="1" colspan="1">0.0509</td><td align="left" rowspan="1" colspan="1"><bold>0.0109</bold><xref ref-type="table-fn" rid="nt103">&#x02020;</xref></td><td align="left" rowspan="1" colspan="1"><bold>0.0037</bold><xref ref-type="table-fn" rid="nt103">&#x02020;</xref></td><td align="left" rowspan="1" colspan="1">0.1331</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">rs1498373</td><td align="left" rowspan="1" colspan="1">T</td><td align="left" rowspan="1" colspan="1"><bold>0.0122</bold><xref ref-type="table-fn" rid="nt103">&#x02020;</xref></td><td align="left" rowspan="1" colspan="1"><bold>0.0171</bold><xref ref-type="table-fn" rid="nt103">&#x02020;</xref></td><td align="left" rowspan="1" colspan="1"><bold>0.0129</bold></td><td align="left" rowspan="1" colspan="1"><bold>0.0459</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">rs233130</td><td align="left" rowspan="1" colspan="1">G</td><td align="left" rowspan="1" colspan="1"><bold>0.0067</bold><xref ref-type="table-fn" rid="nt103">&#x02020;</xref></td><td align="left" rowspan="1" colspan="1"><bold>0.0082</bold><xref ref-type="table-fn" rid="nt103">&#x02020;</xref></td><td align="left" rowspan="1" colspan="1"><bold>0.0063</bold><xref ref-type="table-fn" rid="nt103">&#x02020;</xref></td><td align="left" rowspan="1" colspan="1"><bold>0.0320</bold><xref ref-type="table-fn" rid="nt103">&#x02020;</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">rs233080</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">0.4799</td><td align="left" rowspan="1" colspan="1">0.5185</td><td align="left" rowspan="1" colspan="1">0.6694</td><td align="left" rowspan="1" colspan="1">0.3679</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">rs2474123</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1"><bold>0.0008</bold><xref ref-type="table-fn" rid="nt102">&#x0002a;</xref><xref ref-type="table-fn" rid="nt103">&#x02020;</xref></td><td align="left" rowspan="1" colspan="1"><bold>0.0024</bold><xref ref-type="table-fn" rid="nt103">&#x02020;</xref></td><td align="left" rowspan="1" colspan="1"><bold>0.0032</bold><xref ref-type="table-fn" rid="nt103">&#x02020;</xref></td><td align="left" rowspan="1" colspan="1"><bold>0.0095</bold><xref ref-type="table-fn" rid="nt103">&#x02020;</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">rs986639</td><td align="left" rowspan="1" colspan="1">C</td><td align="left" rowspan="1" colspan="1"><bold>0.0020</bold><xref ref-type="table-fn" rid="nt102">&#x0002a;</xref><xref ref-type="table-fn" rid="nt103">&#x02020;</xref></td><td align="left" rowspan="1" colspan="1"><bold>0.0015</bold><xref ref-type="table-fn" rid="nt102">&#x0002a;</xref><xref ref-type="table-fn" rid="nt103">&#x02020;</xref></td><td align="left" rowspan="1" colspan="1"><bold>0.0093</bold><xref ref-type="table-fn" rid="nt103">&#x02020;</xref></td><td align="left" rowspan="1" colspan="1"><bold>0.0034</bold><xref ref-type="table-fn" rid="nt103">&#x02020;</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">rs12132677</td><td align="left" rowspan="1" colspan="1">C</td><td align="left" rowspan="1" colspan="1">0.3125</td><td align="left" rowspan="1" colspan="1">0.2603</td><td align="left" rowspan="1" colspan="1">0.1188</td><td align="left" rowspan="1" colspan="1">0.3919</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">rs7521189</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1"><bold>6.40E-07</bold><xref ref-type="table-fn" rid="nt102">&#x0002a;</xref><xref ref-type="table-fn" rid="nt103">&#x02020;</xref></td><td align="left" rowspan="1" colspan="1"><bold>3.08E-06</bold><xref ref-type="table-fn" rid="nt102">&#x0002a;</xref><xref ref-type="table-fn" rid="nt103">&#x02020;</xref></td><td align="left" rowspan="1" colspan="1"><bold>0.0073</bold></td><td align="left" rowspan="1" colspan="1"><bold>2.29E-05</bold><xref ref-type="table-fn" rid="nt102">&#x0002a;</xref><xref ref-type="table-fn" rid="nt103">&#x02020;</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">rs17388437</td><td align="left" rowspan="1" colspan="1">C</td><td align="left" rowspan="1" colspan="1">0.2117</td><td align="left" rowspan="1" colspan="1">0.4512</td><td align="left" rowspan="1" colspan="1">0.9184</td><td align="left" rowspan="1" colspan="1">0.2106</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">rs11161614</td><td align="left" rowspan="1" colspan="1">G</td><td align="left" rowspan="1" colspan="1">0.1651</td><td align="left" rowspan="1" colspan="1">0.0799</td><td align="left" rowspan="1" colspan="1">0.0312</td><td align="left" rowspan="1" colspan="1">0.2791</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">rs553257</td><td align="left" rowspan="1" colspan="1">C</td><td align="left" rowspan="1" colspan="1">0.2730</td><td align="left" rowspan="1" colspan="1">0.4311</td><td align="left" rowspan="1" colspan="1">0.2995</td><td align="left" rowspan="1" colspan="1">0.3152</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">rs669173</td><td align="left" rowspan="1" colspan="1">C</td><td align="left" rowspan="1" colspan="1"><bold>8.52E-07</bold><xref ref-type="table-fn" rid="nt102">&#x0002a;</xref><xref ref-type="table-fn" rid="nt103">&#x02020;</xref></td><td align="left" rowspan="1" colspan="1"><bold>2.96E-07</bold><xref ref-type="table-fn" rid="nt102">&#x0002a;</xref><xref ref-type="table-fn" rid="nt103">&#x02020;</xref></td><td align="left" rowspan="1" colspan="1"><bold>0.0006</bold><xref ref-type="table-fn" rid="nt102">&#x0002a;</xref><xref ref-type="table-fn" rid="nt103">&#x02020;</xref></td><td align="left" rowspan="1" colspan="1"><bold>8.48E-06</bold><xref ref-type="table-fn" rid="nt102">&#x0002a;</xref><xref ref-type="table-fn" rid="nt103">&#x02020;</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">13</td><td align="left" rowspan="1" colspan="1">rs539714</td><td align="left" rowspan="1" colspan="1">C</td><td align="left" rowspan="1" colspan="1"><bold>0.0397</bold></td><td align="left" rowspan="1" colspan="1">0.0957</td><td align="left" rowspan="1" colspan="1">0.3206</td><td align="left" rowspan="1" colspan="1"><bold>0.0423</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">14</td><td align="left" rowspan="1" colspan="1">rs11161618</td><td align="left" rowspan="1" colspan="1">T</td><td align="left" rowspan="1" colspan="1">0.1986</td><td align="left" rowspan="1" colspan="1">0.3762</td><td align="left" rowspan="1" colspan="1">0.1887</td><td align="left" rowspan="1" colspan="1">0.3788</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">15</td><td align="left" rowspan="1" colspan="1">rs2935</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1"><bold>0.0402</bold><xref ref-type="table-fn" rid="nt103">&#x02020;</xref></td><td align="left" rowspan="1" colspan="1"><bold>0.0354</bold><xref ref-type="table-fn" rid="nt103">&#x02020;</xref></td><td align="left" rowspan="1" colspan="1"><bold>0.0448</bold></td><td align="left" rowspan="1" colspan="1"><bold>0.0457</bold><xref ref-type="table-fn" rid="nt103">&#x02020;</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">16</td><td align="left" rowspan="1" colspan="1">rs13373844</td><td align="left" rowspan="1" colspan="1">C</td><td align="left" rowspan="1" colspan="1"><bold>0.0065</bold><xref ref-type="table-fn" rid="nt103">&#x02020;</xref></td><td align="left" rowspan="1" colspan="1"><bold>0.0007</bold><xref ref-type="table-fn" rid="nt103">&#x02020;</xref></td><td align="left" rowspan="1" colspan="1"><bold>0.0003</bold><xref ref-type="table-fn" rid="nt102">&#x0002a;</xref><xref ref-type="table-fn" rid="nt103">&#x02020;</xref></td><td align="left" rowspan="1" colspan="1"><bold>0.0447</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">17</td><td align="left" rowspan="1" colspan="1">rs3738111</td><td align="left" rowspan="1" colspan="1">C</td><td align="left" rowspan="1" colspan="1">0.4493</td><td align="left" rowspan="1" colspan="1">0.4404</td><td align="left" rowspan="1" colspan="1">0.4608</td><td align="left" rowspan="1" colspan="1">0.4253</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">18</td><td align="left" rowspan="1" colspan="1">rs877041</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">0.3845</td><td align="left" rowspan="1" colspan="1">0.5145</td><td align="left" rowspan="1" colspan="1">0.2565</td><td align="left" rowspan="1" colspan="1">0.6132</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">19</td><td align="left" rowspan="1" colspan="1">rs12568675</td><td align="left" rowspan="1" colspan="1">C</td><td align="left" rowspan="1" colspan="1"><bold>0.0080</bold><xref ref-type="table-fn" rid="nt103">&#x02020;</xref></td><td align="left" rowspan="1" colspan="1"><bold>0.0086</bold><xref ref-type="table-fn" rid="nt103">&#x02020;</xref></td><td align="left" rowspan="1" colspan="1"><bold>0.0223</bold></td><td align="left" rowspan="1" colspan="1"><bold>0.0102</bold><xref ref-type="table-fn" rid="nt103">&#x02020;</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">20</td><td align="left" rowspan="1" colspan="1">rs974874</td><td align="left" rowspan="1" colspan="1">C</td><td align="left" rowspan="1" colspan="1">0.2716</td><td align="left" rowspan="1" colspan="1">0.5220</td><td align="left" rowspan="1" colspan="1">0.4315</td><td align="left" rowspan="1" colspan="1">0.3135</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">21</td><td align="left" rowspan="1" colspan="1">rs480414</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">0.7295</td><td align="left" rowspan="1" colspan="1">0.9286</td><td align="left" rowspan="1" colspan="1">0.7453</td><td align="left" rowspan="1" colspan="1">0.7703</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">22</td><td align="left" rowspan="1" colspan="1">rs1241321</td><td align="left" rowspan="1" colspan="1">C</td><td align="left" rowspan="1" colspan="1">0.2872</td><td align="left" rowspan="1" colspan="1">0.3422</td><td align="left" rowspan="1" colspan="1">0.1526</td><td align="left" rowspan="1" colspan="1">0.4686</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">23</td><td align="left" rowspan="1" colspan="1">rs587843</td><td align="left" rowspan="1" colspan="1">C</td><td align="left" rowspan="1" colspan="1">0.9023</td><td align="left" rowspan="1" colspan="1">0.7975</td><td align="left" rowspan="1" colspan="1">0.5345</td><td align="left" rowspan="1" colspan="1">0.9364</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">24</td><td align="left" rowspan="1" colspan="1">rs10782551</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">0.9029</td><td align="left" rowspan="1" colspan="1">0.1900</td><td align="left" rowspan="1" colspan="1">0.0844</td><td align="left" rowspan="1" colspan="1">0.8544</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">25</td><td align="left" rowspan="1" colspan="1">rs1403955</td><td align="left" rowspan="1" colspan="1">C</td><td align="left" rowspan="1" colspan="1">0.1959</td><td align="left" rowspan="1" colspan="1">0.3157</td><td align="left" rowspan="1" colspan="1">0.1524</td><td align="left" rowspan="1" colspan="1">0.3582</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">26</td><td align="left" rowspan="1" colspan="1">rs1403951</td><td align="left" rowspan="1" colspan="1">T</td><td align="left" rowspan="1" colspan="1">0.3152</td><td align="left" rowspan="1" colspan="1">0.4972</td><td align="left" rowspan="1" colspan="1">0.2431</td><td align="left" rowspan="1" colspan="1">0.5851</td></tr><tr><td align="left" rowspan="1" colspan="1">DDAH2</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">rs805287</td><td align="left" rowspan="1" colspan="1">C</td><td align="left" rowspan="1" colspan="1">0.4247</td><td align="left" rowspan="1" colspan="1">0.7155</td><td align="left" rowspan="1" colspan="1">0.5545</td><td align="left" rowspan="1" colspan="1">0.4719</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">rs6916278</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">0.9751</td><td align="left" rowspan="1" colspan="1">0.9945</td><td align="left" rowspan="1" colspan="1">0.9164</td><td align="left" rowspan="1" colspan="1">0.9786</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">rs805285</td><td align="left" rowspan="1" colspan="1">G</td><td align="left" rowspan="1" colspan="1">0.1883</td><td align="left" rowspan="1" colspan="1">0.4166</td><td align="left" rowspan="1" colspan="1">0.5521</td><td align="left" rowspan="1" colspan="1">0.1905</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">rs15574</td><td align="left" rowspan="1" colspan="1">T</td><td align="left" rowspan="1" colspan="1">0.2355</td><td align="left" rowspan="1" colspan="1">0.3790</td><td align="left" rowspan="1" colspan="1">0.9151</td><td align="left" rowspan="1" colspan="1">0.1986</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">rs805294</td><td align="left" rowspan="1" colspan="1">C</td><td align="left" rowspan="1" colspan="1">0.4001</td><td align="left" rowspan="1" colspan="1">0.6263</td><td align="left" rowspan="1" colspan="1">0.3565</td><td align="left" rowspan="1" colspan="1">0.5493</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">rs805293</td><td align="left" rowspan="1" colspan="1">T</td><td align="left" rowspan="1" colspan="1">0.7413</td><td align="left" rowspan="1" colspan="1">0.9147</td><td align="left" rowspan="1" colspan="1">0.9231</td><td align="left" rowspan="1" colspan="1">0.6761</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">rs9267551</td><td align="left" rowspan="1" colspan="1">C</td><td align="left" rowspan="1" colspan="1">0.6374</td><td align="left" rowspan="1" colspan="1">0.5282</td><td align="left" rowspan="1" colspan="1">0.2590</td><td align="left" rowspan="1" colspan="1">0.6907</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">rs2272592</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">0.2848</td><td align="left" rowspan="1" colspan="1">0.4027</td><td align="left" rowspan="1" colspan="1">0.2462</td><td align="left" rowspan="1" colspan="1">0.3306</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">rs3131383</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1"><bold>0.0179</bold><xref ref-type="table-fn" rid="nt103">&#x02020;</xref></td><td align="left" rowspan="1" colspan="1"><bold>0.0038</bold><xref ref-type="table-fn" rid="nt102">&#x0002a;</xref><xref ref-type="table-fn" rid="nt103">&#x02020;</xref></td><td align="left" rowspan="1" colspan="1"><bold>0.0029</bold><xref ref-type="table-fn" rid="nt102">&#x0002a;</xref><xref ref-type="table-fn" rid="nt103">&#x02020;</xref></td><td align="left" rowspan="1" colspan="1"><bold>0.0272</bold><xref ref-type="table-fn" rid="nt103">&#x02020;</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">rs3131382</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">0.5141</td><td align="left" rowspan="1" colspan="1">0.8071</td><td align="left" rowspan="1" colspan="1">0.7988</td><td align="left" rowspan="1" colspan="1">0.5127</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt101"><label/><p>Note: p values have been adjusted for duration of diabetes, age, hypertension, smoking, nephropathy and retinopathy status. Results are shown only if genotypes were carried by 5 or more participants. Significant p values are shown in bold type.</p></fn><fn id="nt102"><label/><p>&#x0002a; &#x0200a;&#x0003d;&#x0200a; p-values survive correction for multiple testing.</p></fn><fn id="nt103"><label/><p>&#x02020; &#x0200a;&#x0003d;&#x0200a; p values are also significant in no diabetic retinopathy subset.</p></fn></table-wrap-foot></table-wrap><p>SNP rs3131383 in <italic>DDAH2</italic> was significantly associated with serum ADMA levels (p&#x0200a;&#x0003d;&#x0200a;0.0029 in the dominant model, B: &#x02212;0.03, 95&#x00025; CI: &#x02212;0.06 to &#x02212;0.01, <xref ref-type="table" rid="pone-0009462-t002">Table 2</xref> and <xref ref-type="fig" rid="pone-0009462-g001">Figure 1</xref>). Seven independent tests for <italic>DDAH2</italic> were estimated by the SNPSpD method and after correcting for multiple testing, rs3131383 (p&#x0200a;&#x0003d;&#x0200a;0.034 in the dominant model) remained significantly associated with ADMA levels in all participants (<xref ref-type="table" rid="pone-0009462-t002">Table 2</xref>).</p><p>Sub-analysis by diabetic retinopathy status in the multivariate analyses revealed the majority of these SNPs to be associated with ADMA level only in the subgroup of participants that had no diabetic retinopathy, most significantly rs669173 (p&#x0200a;&#x0003d;&#x0200a;4.66&#x000d7;10<sup>&#x02212;5</sup> in the additive model, B: &#x02212;0.05, 95&#x00025; CI: &#x02212;0.08 to &#x02212;0.03), rs2474123 (p&#x0200a;&#x0003d;&#x0200a;0.00086 in the additive model, B: 0.04, 95&#x00025; CI: 0.01&#x02013;0.06) and rs7521189 (p&#x0200a;&#x0003d;&#x0200a;0.0027 in the additive model, B: &#x02212;0.03, &#x02212;0.06 to &#x02212;0.01, <xref ref-type="table" rid="pone-0009462-t002">Table 2</xref>). These SNPs remained significant after correction for multiple testing. In the blinding diabetic retinopathy cases, rs669173 (p&#x0200a;&#x0003d;&#x0200a;0.017 in the additive model), and rs7521189 (p&#x0200a;&#x0003d;&#x0200a;0.023 in the additive model) were nominally significant, however did not survive correction for multiple testing (<xref ref-type="table" rid="pone-0009462-t002">Table 2</xref>). Although association of rs3131383 in <italic>DDAH2</italic> with ADMA level was not statistically significantly associated in the smaller blinding retinopathy group, the direction of the association with ADMA was the same as that for no retinopathy controls and the full dataset (p&#x0200a;&#x0003d;&#x0200a;0.143, B: &#x02212;0.03 95&#x00025; CI: &#x02212;0.07&#x02013;0.01).</p><p>To assess whether there are additive effects of polymorphisms in the two genes on serum ADMA, the total number of minor alleles of the most significantly associated SNP in each gene (rs669173 and rs3131383) was counted in each individual and included in the linear regression along with the clinical covariates. Multiple minor alleles were associated with lower serum ADMA (Supplementary <xref ref-type="supplementary-material" rid="pone.0009462.s001">Table S1B</xref>). The total number of minor alleles of the two SNPs was significantly associated with ADMA serum level after adjusting for relevant clinical variables (p&#x0200a;&#x0003d;&#x0200a;1.37&#x000d7;10<sup>&#x02212;08</sup>, B: &#x02212;0.03, 95&#x00025; CI: &#x02212;0.04 to &#x02212;0.02, <xref ref-type="table" rid="pone-0009462-t003">Table 3</xref>). This model accounted for more of the variation (r<sup>2</sup>&#x0200a;&#x0003d;&#x0200a;0.147) than including each SNP in the regression as a separate factor with (r<sup>2</sup>&#x0200a;&#x0003d;&#x0200a;0.119) or without (r<sup>2</sup>&#x0200a;&#x0003d;&#x0200a;0.119) an interaction term between the two SNPs. Thus the two genes appear to influence ADMA levels additively.</p><table-wrap id="pone-0009462-t003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0009462.t003</object-id><label>Table 3</label><caption><title>Association of the combination of the most significantly associated <italic>DDAH1</italic> (rs669173) and <italic>DDAH2</italic> (rs3131383) SNPs with serum ADMA levels in all participants.</title></caption><alternatives><graphic id="pone-0009462-t003-3" xlink:href="pone.0009462.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Variable</td><td align="left" rowspan="1" colspan="1">B</td><td align="left" rowspan="1" colspan="1">Lower 95&#x00025; CI</td><td align="left" rowspan="1" colspan="1">Upper 95&#x00025; CI</td><td align="left" rowspan="1" colspan="1">P value</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Combined DDAH1 and 2 SNPs</td><td align="left" rowspan="1" colspan="1">&#x02212;0.03</td><td align="left" rowspan="1" colspan="1">&#x02212;0.04</td><td align="left" rowspan="1" colspan="1">&#x02212;0.02</td><td align="left" rowspan="1" colspan="1">1.37&#x000d7;10<sup>&#x02212;08</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Disease duration</td><td align="left" rowspan="1" colspan="1">0.00</td><td align="left" rowspan="1" colspan="1">0.00</td><td align="left" rowspan="1" colspan="1">0.00</td><td align="left" rowspan="1" colspan="1">0.006</td></tr><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="left" rowspan="1" colspan="1">0.00</td><td align="left" rowspan="1" colspan="1">0.00</td><td align="left" rowspan="1" colspan="1">0.00</td><td align="left" rowspan="1" colspan="1">0.319</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypertension</td><td align="left" rowspan="1" colspan="1">0.01</td><td align="left" rowspan="1" colspan="1">&#x02212;0.01</td><td align="left" rowspan="1" colspan="1">0.03</td><td align="left" rowspan="1" colspan="1">0.431</td></tr><tr><td align="left" rowspan="1" colspan="1">Smoking</td><td align="left" rowspan="1" colspan="1">0.02</td><td align="left" rowspan="1" colspan="1">0.01</td><td align="left" rowspan="1" colspan="1">0.04</td><td align="left" rowspan="1" colspan="1">0.011</td></tr><tr><td align="left" rowspan="1" colspan="1">Nephropathy</td><td align="left" rowspan="1" colspan="1">0.01</td><td align="left" rowspan="1" colspan="1">0.00</td><td align="left" rowspan="1" colspan="1">0.03</td><td align="left" rowspan="1" colspan="1">0.144</td></tr><tr><td align="left" rowspan="1" colspan="1">DR</td><td align="left" rowspan="1" colspan="1">0.01</td><td align="left" rowspan="1" colspan="1">0.00</td><td align="left" rowspan="1" colspan="1">0.03</td><td align="left" rowspan="1" colspan="1">0.121</td></tr><tr><td align="left" rowspan="1" colspan="1">(Constant)</td><td align="left" rowspan="1" colspan="1">0.73</td><td align="left" rowspan="1" colspan="1">0.66</td><td align="left" rowspan="1" colspan="1">0.81</td><td align="left" rowspan="1" colspan="1"/></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt104"><label/><p>B&#x0200a;&#x0003d;&#x0200a;beta coefficient.</p></fn></table-wrap-foot></table-wrap><p>For the haplotype analyses, observation of the <italic>DDAH</italic> SNPs in HapMap revealed three blocks of linkage disequilibrium in <italic>DDAH1</italic> and one block in <italic>DDAH2</italic> (<xref ref-type="table" rid="pone-0009462-t004">Table 4</xref>). As block 2 of <italic>DDAH1</italic> consisted of 11 tag SNPs, it was further subdivided into two blocks for the haplotype analyses. After adjusting for associated variables in the multivariate analyses, several <italic>DDAH1</italic> haplotypes were significantly associated with ADMA levels, with the GAATTT haplotype of block 2A (p&#x0200a;&#x0003d;&#x0200a;0.00012, B: &#x02212;0.03, 95&#x00025; CI: &#x02212;0.04 to &#x02212;0.01, <xref ref-type="table" rid="pone-0009462-t004">Table 4</xref> and <xref ref-type="fig" rid="pone-0009462-g001">Figure 1</xref>), and the <named-content content-type="gene">TATAGTGGAG</named-content> haplotype of block 3 (p&#x0200a;&#x0003d;&#x0200a;0.00074, B: &#x02212;0.02, 95&#x00025; CI: &#x02212;0.04 to &#x02212;0.01) being the most significantly associated (<xref ref-type="table" rid="pone-0009462-t004">Table 4</xref>). The <named-content content-type="gene">TGCCCAGGAG</named-content> of <italic>DDAH2</italic> was significantly associated with serum ADMA levels (p&#x0200a;&#x0003d;&#x0200a;0.0012 B: &#x02212;0.03 95&#x00025; CI: &#x02212;0.05 to &#x02212;0.01, <xref ref-type="table" rid="pone-0009462-t004">Table 4</xref> and <xref ref-type="fig" rid="pone-0009462-g001">Figure 1</xref>). Seven haplotypes remained significant after Bonferroni correction (<xref ref-type="table" rid="pone-0009462-t004">Table 4</xref>). Sub-analysis by diabetic retinopathy status revealed 5 of these haplotypes in <italic>DDAH1</italic> and the single associated haplotype in <italic>DDAH2</italic> to be significantly associated with serum ADMA level in the no diabetic retinopathy subgroup (<xref ref-type="table" rid="pone-0009462-t004">Table 4</xref>) in the multivariate analyses. No haplotypes were associated with ADMA level in the blinding diabetic retinopathy subgroup after correction for multiple testing.</p><table-wrap id="pone-0009462-t004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0009462.t004</object-id><label>Table 4</label><caption><title>Association of common <italic>DDAH</italic> haplotypes (&#x0003e;2&#x00025; frequency) with ADMA levels.</title></caption><alternatives><graphic id="pone-0009462-t004-4" xlink:href="pone.0009462.t004"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"><italic>DDAH</italic> gene</td><td align="left" rowspan="1" colspan="1">Haplotype block</td><td align="left" rowspan="1" colspan="1">Haplotype</td><td align="left" rowspan="1" colspan="1">Haplotype frequency</td><td align="left" rowspan="1" colspan="1">P value</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">Block 1</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">ACAGG</named-content></td><td align="left" rowspan="1" colspan="1">0.055</td><td align="left" rowspan="1" colspan="1"><bold>0.0483</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">(SNPs 1&#x02013;5)</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">ACAGA</named-content></td><td align="left" rowspan="1" colspan="1">0.091</td><td align="left" rowspan="1" colspan="1">0.2800</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">GCAGG</named-content></td><td align="left" rowspan="1" colspan="1">0.236</td><td align="left" rowspan="1" colspan="1"><bold>0.0027</bold><xref ref-type="table-fn" rid="nt106">&#x0002a;</xref><xref ref-type="table-fn" rid="nt107">&#x02020;</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">ACAAG</named-content></td><td align="left" rowspan="1" colspan="1">0.287</td><td align="left" rowspan="1" colspan="1">0.9190</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">ATGGA</named-content></td><td align="left" rowspan="1" colspan="1">0.326</td><td align="left" rowspan="1" colspan="1"><bold>0.0023</bold><xref ref-type="table-fn" rid="nt106">&#x0002a;</xref><xref ref-type="table-fn" rid="nt107">&#x02020;</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">Block 2A</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">CAGTGT</named-content></td><td align="left" rowspan="1" colspan="1">0.034</td><td align="left" rowspan="1" colspan="1">0.1410</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">(SNPs 6&#x02013;11)</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">GAGCTT</named-content></td><td align="left" rowspan="1" colspan="1">0.035</td><td align="left" rowspan="1" colspan="1">0.6610</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">GCGTGT</named-content></td><td align="left" rowspan="1" colspan="1">0.084</td><td align="left" rowspan="1" colspan="1">0.6920</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">CCGTGT</named-content></td><td align="left" rowspan="1" colspan="1">0.098</td><td align="left" rowspan="1" colspan="1"><bold>0.0044</bold><xref ref-type="table-fn" rid="nt106">&#x0002a;</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">GAATTC</named-content></td><td align="left" rowspan="1" colspan="1">0.187</td><td align="left" rowspan="1" colspan="1">0.3250</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">GAGTTT</named-content></td><td align="left" rowspan="1" colspan="1">0.256</td><td align="left" rowspan="1" colspan="1"><bold>0.0139</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">GAATTT</named-content></td><td align="left" rowspan="1" colspan="1">0.279</td><td align="left" rowspan="1" colspan="1"><bold>0.0001</bold><xref ref-type="table-fn" rid="nt106">&#x0002a;</xref><xref ref-type="table-fn" rid="nt107">&#x02020;</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">Block 2B</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">CTCGC</named-content></td><td align="left" rowspan="1" colspan="1">0.051</td><td align="left" rowspan="1" colspan="1"><bold>0.0252</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">(SNPs 12&#x02013;16)</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">TTCAA</named-content></td><td align="left" rowspan="1" colspan="1">0.091</td><td align="left" rowspan="1" colspan="1"><bold>0.0203</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">TTCGA</named-content></td><td align="left" rowspan="1" colspan="1">0.124</td><td align="left" rowspan="1" colspan="1">0.0934</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">TCCGA</named-content></td><td align="left" rowspan="1" colspan="1">0.144</td><td align="left" rowspan="1" colspan="1">0.1960</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">CTCGA</named-content></td><td align="left" rowspan="1" colspan="1">0.149</td><td align="left" rowspan="1" colspan="1">0.0844</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">TTTGA</td><td align="left" rowspan="1" colspan="1">0.193</td><td align="left" rowspan="1" colspan="1">0.0561</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">CTTGC</named-content></td><td align="left" rowspan="1" colspan="1">0.224</td><td align="left" rowspan="1" colspan="1"><bold>0.0030</bold><xref ref-type="table-fn" rid="nt106">&#x0002a;</xref><xref ref-type="table-fn" rid="nt107">&#x02020;</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">Block 3</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">TATAGTGGAG</named-content></td><td align="left" rowspan="1" colspan="1">0.276</td><td align="left" rowspan="1" colspan="1"><bold>0.0007</bold><xref ref-type="table-fn" rid="nt106">&#x0002a;</xref><xref ref-type="table-fn" rid="nt107">&#x02020;</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">(SNPs 17&#x02013;26)</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">TACAGCGGAG</named-content></td><td align="left" rowspan="1" colspan="1">0.093</td><td align="left" rowspan="1" colspan="1"><bold>0.0041</bold><xref ref-type="table-fn" rid="nt106">&#x0002a;</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">TGTAACCAAG</named-content></td><td align="left" rowspan="1" colspan="1">0.084</td><td align="left" rowspan="1" colspan="1">0.0553</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">TGTAGTCGAG</named-content></td><td align="left" rowspan="1" colspan="1">0.036</td><td align="left" rowspan="1" colspan="1">0.2330</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">TGTAACCGCT</named-content></td><td align="left" rowspan="1" colspan="1">0.101</td><td align="left" rowspan="1" colspan="1">0.2830</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">TGTCGTGGCT</named-content></td><td align="left" rowspan="1" colspan="1">0.260</td><td align="left" rowspan="1" colspan="1">0.5820</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">TGTAACGGAG</named-content></td><td align="left" rowspan="1" colspan="1">0.027</td><td align="left" rowspan="1" colspan="1">0.8180</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">CGTAATCGAT</named-content></td><td align="left" rowspan="1" colspan="1">0.080</td><td align="left" rowspan="1" colspan="1">0.9550</td></tr><tr><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">Block 1</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">CGCCTTGGCG</named-content></td><td align="left" rowspan="1" colspan="1">0.043</td><td align="left" rowspan="1" colspan="1">0.8070</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">(All SNPs)</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">TGCCTACACA</named-content></td><td align="left" rowspan="1" colspan="1">0.052</td><td align="left" rowspan="1" colspan="1">0.3660</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">TGCCTACACG</named-content></td><td align="left" rowspan="1" colspan="1">0.052</td><td align="left" rowspan="1" colspan="1">0.2750</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">TGCCTAGACG</named-content></td><td align="left" rowspan="1" colspan="1">0.054</td><td align="left" rowspan="1" colspan="1">0.9140</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">CGGCCAGGCG</named-content></td><td align="left" rowspan="1" colspan="1">0.064</td><td align="left" rowspan="1" colspan="1">0.3470</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">TACCTTGGCG</named-content></td><td align="left" rowspan="1" colspan="1">0.067</td><td align="left" rowspan="1" colspan="1">0.9030</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">TGCCCAGGAG</named-content></td><td align="left" rowspan="1" colspan="1">0.111</td><td align="left" rowspan="1" colspan="1"><bold>0.0012</bold><xref ref-type="table-fn" rid="nt106">&#x0002a;</xref><xref ref-type="table-fn" rid="nt107">&#x02020;</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">CGGTCAGGCG</named-content></td><td align="left" rowspan="1" colspan="1">0.199</td><td align="left" rowspan="1" colspan="1">0.9650</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">TGCCTTGGCG</named-content></td><td align="left" rowspan="1" colspan="1">0.348</td><td align="left" rowspan="1" colspan="1">0.8960</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt105"><label/><p>Note: SNPs correspond to the order of those shown in <xref ref-type="table" rid="pone-0009462-t002">Table 2</xref>. P values have been adjusted for duration of diabetes, age, hypertension, smoking, nephropathy and retinopathy status. Significant p values are shown in bold type.</p></fn><fn id="nt106"><label/><p>&#x0002a; &#x0200a;&#x0003d;&#x0200a; p values survive correction for multiple testing.</p></fn><fn id="nt107"><label/><p>&#x02020; &#x0200a;&#x0003d;&#x0200a; p values are also significant in no diabetic retinopathy subset.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3"><title>Discussion</title><p>This study found genetic variation in the <italic>DDAH1</italic> and <italic>DDAH2</italic> genes to be significantly associated with serum ADMA levels in participants with type 2 diabetes. To our knowledge, this is the first study of its kind to investigate genetic variation in DDAH genes and their association with serum ADMA levels in patients with type 2 diabetes.</p><p>ADMA is an endogenous inhibitor of NOS and therefore NO bioavailability. The role of NO in the development of insulin resistance is supported by eNOS <xref ref-type="bibr" rid="pone.0009462-Duplain1">&#x0005b;19&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009462-Shankar1">&#x0005b;20&#x0005d;</xref> and nNOS <xref ref-type="bibr" rid="pone.0009462-Shankar1">&#x0005b;20&#x0005d;</xref> knockout mice studies. Similarly, previous studies have shown serum ADMA elevation to be significantly associated with diabetes <xref ref-type="bibr" rid="pone.0009462-Abbasi1">&#x0005b;5&#x0005d;</xref> and insulin resistance <xref ref-type="bibr" rid="pone.0009462-Stuhlinger1">&#x0005b;21&#x0005d;</xref> in humans. Animal studies have also supported the role of ADMA in insulin resistance, with DDAH expression shown to play a role <xref ref-type="bibr" rid="pone.0009462-Sydow1">&#x0005b;22&#x0005d;</xref>. When compared to wild type mice, in response to a glucose challenge, Sydow <italic>et al</italic> found DDAH1 transgenic mice to show a blunted increase in ADMA, plasma insulin and glucose <xref ref-type="bibr" rid="pone.0009462-Sydow1">&#x0005b;22&#x0005d;</xref>. Hyperglycemia has also been shown to lead to decreased DDAH activity and subsequent ADMA elevation <xref ref-type="bibr" rid="pone.0009462-Lin1">&#x0005b;23&#x0005d;</xref>. A variety of other factors have also been shown to be involved in control of <italic>DDAH</italic> expression and activity. For example, oxidative stress and inflammation in cultured human endothelial cells decreases DDAH activity and upregulates ADMA synthesis <xref ref-type="bibr" rid="pone.0009462-Forbes1">&#x0005b;24&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009462-Ito1">&#x0005b;25&#x0005d;</xref> subsequently leading to a reduction in NO synthesis <xref ref-type="bibr" rid="pone.0009462-MacAllister1">&#x0005b;26&#x0005d;</xref>. Variation in the promoter region of <italic>DDAH2</italic> influences its expression <xref ref-type="bibr" rid="pone.0009462-Jones1">&#x0005b;27&#x0005d;</xref>. Increased NO has also been shown to upregulate <italic>DDAH2</italic> expression in cultured rat aortic endothelial cells, indicating a possible positive feedback mechanism <xref ref-type="bibr" rid="pone.0009462-Sakurada1">&#x0005b;28&#x0005d;</xref>.</p><p>NO is also a key player in protection against microvascular damage <xref ref-type="bibr" rid="pone.0009462-Toda1">&#x0005b;6&#x0005d;</xref>, and serum ADMA levels have been found to be increased in conditions associated with endothelial dysfunction, including hypertension, hypercholesterolemia, hyperhomocysteinemia <xref ref-type="bibr" rid="pone.0009462-Boger1">&#x0005b;29&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009462-Stuhlinger2">&#x0005b;30&#x0005d;</xref> and diabetic retinopathy <xref ref-type="bibr" rid="pone.0009462-Makino1">&#x0005b;7&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009462-Malecki1">&#x0005b;8&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009462-Sugai1">&#x0005b;9&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009462-Abhary1">&#x0005b;10&#x0005d;</xref>. Although DDAHI is primarily expressed in tissues producing nNOS <xref ref-type="bibr" rid="pone.0009462-Leiper1">&#x0005b;15&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009462-Tran2">&#x0005b;16&#x0005d;</xref> and DDAHII in tissues producing eNOS and iNOS <xref ref-type="bibr" rid="pone.0009462-Tran2">&#x0005b;16&#x0005d;</xref>, all three isoforms of NOS have been isolated from the retina <xref ref-type="bibr" rid="pone.0009462-Connell1">&#x0005b;31&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009462-Carmo1">&#x0005b;32&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009462-Yuan1">&#x0005b;33&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009462-AbuElAsrar1">&#x0005b;34&#x0005d;</xref>. Decreased retinal expression of eNOS <xref ref-type="bibr" rid="pone.0009462-Connell1">&#x0005b;31&#x0005d;</xref> and increased expression of iNOS <xref ref-type="bibr" rid="pone.0009462-Carmo1">&#x0005b;32&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009462-Yuan1">&#x0005b;33&#x0005d;</xref> and nNOS <xref ref-type="bibr" rid="pone.0009462-AbuElAsrar1">&#x0005b;34&#x0005d;</xref> have been shown to be associated with hyperglycemia and diabetic retinopathy in both animal and human studies.</p><p>ADMA is present in the aqueous humor of the human eye. In a recent proteomic study with relatively small numbers, aqueous humor and serum ADMA levels were significantly higher in subjects with diabetes and those with severe diabetic retinopathy when compared to non-diabetic controls <xref ref-type="bibr" rid="pone.0009462-Sugai1">&#x0005b;9&#x0005d;</xref>. Sub-analysis by diabetic retinopathy status in this study revealed serum ADMA levels to be associated with common genetic variation in <italic>DDAH</italic> genes, primarily in our cohort of individuals with type 2 diabetes <italic>without</italic> diabetic retinopathy. However, for the mostly significantly associated SNPs, the serum ADMA levels trend in the same direction, and a true association may exist in the smaller retinopathy cohort which is less powered to detect the effect. The participants with no diabetic retinopathy had significantly lower ADMA levels compared to those with diabetic retinopathy <xref ref-type="bibr" rid="pone.0009462-Abhary1">&#x0005b;10&#x0005d;</xref>. Although the lack of highly significant association in the retinopathy group is likely attributable to power, it is possible that other influences play a greater role in determining serum ADMA levels once microvascular damage has occurred. Impairment of ADMA metabolism may occur due to oxidative stress and inflammation involved in endothelial dysfunction and microvascular damage. However, some studies have found elevated retinal NO in proliferative diabetic retinopathy <xref ref-type="bibr" rid="pone.0009462-Tsai1">&#x0005b;35&#x0005d;</xref>, therefore ADMA elevation may actually be a compensatory mechanism to decrease pathologically elevated NO. It remains unclear whether ADMA elevation in diabetic retinopathy is a causal association or occurs as a result of endothelial dysfunction, and these potential mechanisms are not mutually exclusive.</p><p>Diabetic retinopathy is a debilitating complication of diabetes mellitus with a multifactorial pathogenesis and limited treatment options. Further prospective and functional studies investigating the pathophysiological significance of elevated serum ADMA in the development of diabetic retinopathy and other diabetes complications are required. Ultimately, if causal relationships are established, this could lead to design of future therapeutic or preventative strategies to correct NO levels in the ocular environment, thereby retarding or preventing the development of diabetic retinopathy.</p><p>Many of the most significantly associated <italic>DDAH1</italic> SNPs in this study are located in intron 1 of the gene. The significantly associated <italic>DDAH2</italic> SNP (rs3131383), although within the block of linkage disequilibrium that contains <italic>DDAH2</italic>, is actually within the chloride intracellular channel 1 (<italic>CLIC1</italic>) gene and 6255 bp from the <italic>DDAH2</italic> transcription start site. <italic>CLIC1</italic> encodes chloride ion channels that regulate fundamental cellular processes including transepithelial transport, maintenance of intracellular pH, and regulation of cell volume and cell cycle <xref ref-type="bibr" rid="pone.0009462-Ducharme1">&#x0005b;36&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009462-Fanucchi1">&#x0005b;37&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009462-Valenzuela1">&#x0005b;38&#x0005d;</xref>. No associations have been reported between <italic>CLIC1</italic> and serum DDAH or ADMA. The associated SNPs in both genes could either tag functional SNPs that affect expression level (eg promoter or other regulatory variants), or coding variants that affect DDAH protein activity. Very few if any common coding variants have been reported in these genes and therefore deep resequencing may be required to determine if they do exist.</p><p>In conclusion, genetic variation in <italic>DDAH1</italic> and <italic>DDAH2</italic> genes was found to be strongly and significantly associated with serum ADMA levels in patients with type 2 diabetes, especially in those without retinopathy. Further studies are required to assess <italic>DDAH</italic> sequence variation and its influence on DDAH activity and serum ADMA levels both in individuals with and without diabetes to increase understanding of this complex pathway in normal and pathogenic conditions.</p></sec><sec id="s4" sec-type="methods"><title>Methods</title><sec id="s4a"><title>Ethics Statement</title><p>Ethics approval was obtained from the Human Research Ethics Committees of Flinders Medical Centre, Royal Adelaide Hospital and Queen Elizabeth Hospital in Adelaide, Australia, and written informed consent was obtained from all participants.</p></sec><sec id="s4b"><title>Subject Recruitment</title><p>Subjects were recruited from ophthalmology and endocrinology outpatient clinics of three tertiary hospitals in metropolitan Adelaide, South Australia, initially to study the genetics of blinding diabetic retinopathy. Participants were over 18 years of age and were required to have type 2 diabetes of at least 5 years duration and be on oral hypoglycemic or insulin therapy.</p><p>A detailed questionnaire containing information regarding sex, age, ethnicity, age at diagnosis of diabetes, family diabetic history, co-existing risk factors, systemic complications of diabetes, ocular complications as a result of diabetic retinopathy, past ocular history, smoking history and alcohol intake was conducted in person for each participant. Renal function tests &#x0005b;serum creatinine, urine albumin and albumin&#x02236;creatinine ratio and glomerular filtration rate (GFR)&#x0005d;, serum cholesterol and HbA1c levels were obtained from a state-wide database. Three recent HbA1c levels were averaged for each participant. For those cases diagnosed with blinding DR, HbA1c levels at the time of the ocular complication were used, and for controls with DM, HbA1c levels immediately prior to recruitment were averaged.</p><p>Peripheral whole blood was obtained from each participant and DNA extracted using the QiaAmp Blood Maxi Kit (Qiagen, Valencia, CA, USA). Blood pressure and body mass index (BMI) were measured in each participant. Patients were classified as hypertensive if they were on treatment for hypertension, or they had a blood pressure reading greater than or equal to 140/90 mmHg at the time of recruitment. Hypercholesterolemia was defined as total cholesterol of greater than 5.5 mmol/L, or current use of lipid lowering medication. Retinopathy status for the worst eye was clinically graded by an ophthalmologist according to the Early Treatment Diabetic Retinopathy Study criteria <xref ref-type="bibr" rid="pone.0009462-1">&#x0005b;39&#x0005d;</xref>. Participants were only included if they had either no retinopathy, or blinding retinopathy defined as severe non-proliferative diabetic retinopathy, proliferative diabetic retinopathy, or clinically significant macular edema. Nephropathy was defined as the presence of microalbuminuria (30&#x02013;300 mg/day) or macroalbuminuria (&#x0003e;300 mg/day).</p></sec><sec id="s4c"><title><italic>DDAH</italic> SNP Selection and Genotyping</title><p>Using the tagger program implemented in Haploview 4.0 <xref ref-type="bibr" rid="pone.0009462-Barrett1">&#x0005b;40&#x0005d;</xref>, tag single nucleotide polymorphisms (SNPs) across <italic>DDAH1</italic> and <italic>DDAH2</italic> genes, including the promoter region, were selected on the basis of linkage disequilibrium patterns observed in the Caucasian (CEU) samples genotyped as part of the International HapMap Project <xref ref-type="bibr" rid="pone.0009462-2">&#x0005b;41&#x0005d;</xref>. Only SNPs with minor allele frequency greater than 5&#x00025; in HapMap were considered. Twenty six <italic>DDAH1</italic> and 10 <italic>DDAH2</italic> tag SNPs (<xref ref-type="table" rid="pone-0009462-t002">Table 2</xref>) which captured all alleles with an r<sup>2</sup> of at least 0.8 (mean r<sup>2</sup>&#x0200a;&#x0003d;&#x0200a;0.95), were genotyped in all individuals on the Sequenom iPLEX GOLD chemistry on an Autoflex Mass Spectrometer at the Australian Genome Research Facility, Brisbane, Australia.</p></sec><sec id="s4d"><title>Measurement of Serum Concentrations of ADMA, SDMA and Arginine</title><p>Serum ADMA concentrations were determined in all participants <xref ref-type="bibr" rid="pone.0009462-Abhary1">&#x0005b;10&#x0005d;</xref> by liquid chromatography-tandem mass spectrometry of the butyl esters on an Applied Biosystems 3200 Q-Trap instrument (Applied Biosystems, Scoresby, Victoria), as described by Schwedhelm et al <xref ref-type="bibr" rid="pone.0009462-Schwedhelm1">&#x0005b;42&#x0005d;</xref>. &#x000ae;Deuterated internal standards (98 atom&#x00025; <sup>2</sup>H isotopic purity) were purchased from Cambridge Isotope Laboratories (Andover, MA) and were L-&#x0005b;<sup>2</sup>H<sub>7</sub>&#x0005d;-arginine for arginine quantitation and 2,3,3,4,4,5,5-&#x0005b;<sup>2</sup>H<sub>7</sub>&#x0005d;-ADMA for ADMA analyses. The between-run coefficient of variation for ADMA was determined as 4.0&#x00025; at a concentration of 0.48 &#x000b5;mol/L.</p></sec><sec id="s4e"><title>Statistical Analyses</title><p>Pearson correlation was undertaken for associations of clinical covariates with ADMA levels in SPSS (v15.0 SPSS Inc, Chicago, IL). Differences in clinical covariates between patients with and without diabetic retinopathy were calculated by Student's t-test or the chi-square test. ADMA levels were log transformed to approximate a normal distribution. Genotypic associations for all SNPs were assessed in PLINK (v1.06) <xref ref-type="bibr" rid="pone.0009462-Purcell1">&#x0005b;43&#x0005d;</xref>. Dominant, additive, recessive and genotypic models were considered with respect to the minor allele. Haplotypic analyses were performed in accordance with the observed linkage disequilibrium (LD) patterns in the Caucasian sample in HapMap. Multiple testing of individual SNPs was adjusted for using the Single Nucleotide Polymorphism Spectral Decomposition (SNPSpD) method of Nyholt <xref ref-type="bibr" rid="pone.0009462-Nyholt1">&#x0005b;44&#x0005d;</xref> modified by Li and Ji <xref ref-type="bibr" rid="pone.0009462-Li1">&#x0005b;45&#x0005d;</xref> and Bonferroni correction was applied to haplotype analyses.</p></sec></sec><sec sec-type="supplementary-material" id="s5"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pone.0009462.s001"><label>Table S1</label><caption><p>(0.21 MB DOC)</p></caption><media xlink:href="pone.0009462.s001.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ref-list><title>Refrences</title><ref id="pone.0009462-Dimmeler1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dimmeler</surname><given-names>S</given-names></name><name><surname>Hermann</surname><given-names>C</given-names></name><name><surname>Galle</surname><given-names>J</given-names></name><name><surname>Zeiher</surname><given-names>AM</given-names></name></person-group><year>1999</year><article-title>Upregulation of superoxide dismutase and nitric oxide synthase mediates the apoptosis-suppressive effects of shear stress on endothelial cells.</article-title><source>Arterioscler Thromb Vasc Biol</source><volume>19</volume><fpage>656</fpage><lpage>664</lpage><pub-id pub-id-type="pmid">10073970</pub-id></mixed-citation></ref><ref id="pone.0009462-Wang1"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>BY</given-names></name><name><surname>Ho</surname><given-names>HK</given-names></name><name><surname>Lin</surname><given-names>PS</given-names></name><name><surname>Schwarzacher</surname><given-names>SP</given-names></name><name><surname>Pollman</surname><given-names>MJ</given-names></name><etal/></person-group><year>1999</year><article-title>Regression of atherosclerosis: role of nitric oxide and apoptosis.</article-title><source>Circulation</source><volume>99</volume><fpage>1236</fpage><lpage>1241</lpage><pub-id pub-id-type="pmid">10069793</pub-id></mixed-citation></ref><ref id="pone.0009462-Stamler1"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stamler</surname><given-names>J</given-names></name><name><surname>Mendelsohn</surname><given-names>ME</given-names></name><name><surname>Amarante</surname><given-names>P</given-names></name><name><surname>Smick</surname><given-names>D</given-names></name><name><surname>Andon</surname><given-names>N</given-names></name><etal/></person-group><year>1989</year><article-title>N-acetylcysteine potentiates platelet inhibition by endothelium-derived relaxing factor.</article-title><source>Circ Res</source><volume>65</volume><fpage>789</fpage><lpage>795</lpage><pub-id pub-id-type="pmid">2548765</pub-id></mixed-citation></ref><ref id="pone.0009462-Oelze1"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oelze</surname><given-names>M</given-names></name><name><surname>Mollnau</surname><given-names>H</given-names></name><name><surname>Hoffmann</surname><given-names>N</given-names></name><name><surname>Warnholtz</surname><given-names>A</given-names></name><name><surname>Bodenschatz</surname><given-names>M</given-names></name><etal/></person-group><year>2000</year><article-title>Vasodilator-stimulated phosphoprotein serine 239 phosphorylation as a sensitive monitor of defective nitric oxide/cGMP signaling and endothelial dysfunction.</article-title><source>Circ Res</source><volume>87</volume><fpage>999</fpage><lpage>1005</lpage><pub-id pub-id-type="pmid">11090544</pub-id></mixed-citation></ref><ref id="pone.0009462-Abbasi1"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abbasi</surname><given-names>F</given-names></name><name><surname>Asagmi</surname><given-names>T</given-names></name><name><surname>Cooke</surname><given-names>JP</given-names></name><name><surname>Lamendola</surname><given-names>C</given-names></name><name><surname>McLaughlin</surname><given-names>T</given-names></name><etal/></person-group><year>2001</year><article-title>Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus.</article-title><source>Am J Cardiol</source><volume>88</volume><fpage>1201</fpage><lpage>1203</lpage><pub-id pub-id-type="pmid">11703973</pub-id></mixed-citation></ref><ref id="pone.0009462-Toda1"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toda</surname><given-names>N</given-names></name><name><surname>Nakanishi-Toda</surname><given-names>M</given-names></name></person-group><year>2007</year><article-title>Nitric oxide: ocular blood flow, glaucoma, and diabetic retinopathy.</article-title><source>Prog Retin Eye Res</source><volume>26</volume><fpage>205</fpage><lpage>238</lpage><pub-id pub-id-type="pmid">17337232</pub-id></mixed-citation></ref><ref id="pone.0009462-Makino1"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Makino</surname><given-names>N</given-names></name><name><surname>Maeda</surname><given-names>T</given-names></name><name><surname>Sugano</surname><given-names>M</given-names></name><name><surname>Satoh</surname><given-names>S</given-names></name><name><surname>Watanabe</surname><given-names>R</given-names></name><etal/></person-group><year>2005</year><article-title>High serum TNF-alpha level in Type 2 diabetic patients with microangiopathy is associated with eNOS down-regulation and apoptosis in endothelial cells.</article-title><source>J Diabetes Complications</source><volume>19</volume><fpage>347</fpage><lpage>355</lpage><pub-id pub-id-type="pmid">16260352</pub-id></mixed-citation></ref><ref id="pone.0009462-Malecki1"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malecki</surname><given-names>MT</given-names></name><name><surname>Undas</surname><given-names>A</given-names></name><name><surname>Cyganek</surname><given-names>K</given-names></name><name><surname>Mirkiewicz-Sieradzka</surname><given-names>B</given-names></name><name><surname>Wolkow</surname><given-names>P</given-names></name><etal/></person-group><year>2007</year><article-title>Plasma asymmetric dimethylarginine (ADMA) is associated with retinopathy in type 2 diabetes.</article-title><source>Diabetes Care</source><volume>30</volume><fpage>2899</fpage><lpage>2901</lpage><pub-id pub-id-type="pmid">17704346</pub-id></mixed-citation></ref><ref id="pone.0009462-Sugai1"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sugai</surname><given-names>M</given-names></name><name><surname>Ohta</surname><given-names>A</given-names></name><name><surname>Ogata</surname><given-names>Y</given-names></name><name><surname>Nakanishi</surname><given-names>M</given-names></name><name><surname>Ueno</surname><given-names>S</given-names></name><etal/></person-group><year>2007</year><article-title>Asymmetric dimethylarginine (ADMA) in the aqueous humor of diabetic patients.</article-title><source>Endocr J</source><volume>54</volume><fpage>303</fpage><lpage>309</lpage><pub-id pub-id-type="pmid">17379959</pub-id></mixed-citation></ref><ref id="pone.0009462-Abhary1"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abhary</surname><given-names>S</given-names></name><name><surname>Kasmeridis</surname><given-names>N</given-names></name><name><surname>Burdon</surname><given-names>KP</given-names></name><name><surname>Kuot</surname><given-names>A</given-names></name><name><surname>Whiting</surname><given-names>MJ</given-names></name><etal/></person-group><year>2009</year><article-title>Diabetic retinopathy is associated with elevated serum asymmetric and symmetric dimethylarginines.</article-title><source>Diabetes Care</source></mixed-citation></ref><ref id="pone.0009462-Hanai1"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanai</surname><given-names>K</given-names></name><name><surname>Babazono</surname><given-names>T</given-names></name><name><surname>Nyumura</surname><given-names>I</given-names></name><name><surname>Toya</surname><given-names>K</given-names></name><name><surname>Tanaka</surname><given-names>N</given-names></name><etal/></person-group><year>2009</year><article-title>Asymmetric dimethylarginine is closely associated with the development and progression of nephropathy in patients with type 2 diabetes.</article-title><source>Nephrol Dial Transplant</source><volume>24</volume><fpage>1884</fpage><lpage>1888</lpage><pub-id pub-id-type="pmid">19131352</pub-id></mixed-citation></ref><ref id="pone.0009462-Achan1"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Achan</surname><given-names>V</given-names></name><name><surname>Broadhead</surname><given-names>M</given-names></name><name><surname>Malaki</surname><given-names>M</given-names></name><name><surname>Whitley</surname><given-names>G</given-names></name><name><surname>Leiper</surname><given-names>J</given-names></name><etal/></person-group><year>2003</year><article-title>Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase.</article-title><source>Arterioscler Thromb Vasc Biol</source><volume>23</volume><fpage>1455</fpage><lpage>1459</lpage><pub-id pub-id-type="pmid">12805079</pub-id></mixed-citation></ref><ref id="pone.0009462-Teerlink1"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teerlink</surname><given-names>T</given-names></name></person-group><year>2005</year><article-title>ADMA metabolism and clearance.</article-title><source>Vasc Med</source><volume>10</volume><issue>Suppl 1</issue><fpage>S73</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">16444872</pub-id></mixed-citation></ref><ref id="pone.0009462-Tran1"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tran</surname><given-names>CT</given-names></name><name><surname>Leiper</surname><given-names>JM</given-names></name><name><surname>Vallance</surname><given-names>P</given-names></name></person-group><year>2003</year><article-title>The DDAH/ADMA/NOS pathway.</article-title><source>Atheroscler</source><issue>Suppl 4</issue><fpage>33</fpage><lpage>40</lpage></mixed-citation></ref><ref id="pone.0009462-Leiper1"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leiper</surname><given-names>JM</given-names></name><name><surname>Santa Maria</surname><given-names>J</given-names></name><name><surname>Chubb</surname><given-names>A</given-names></name><name><surname>MacAllister</surname><given-names>RJ</given-names></name><name><surname>Charles</surname><given-names>IG</given-names></name><etal/></person-group><year>1999</year><article-title>Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases.</article-title><source>Biochem J</source><volume>343 Pt 1</volume><fpage>209</fpage><lpage>214</lpage><pub-id pub-id-type="pmid">10493931</pub-id></mixed-citation></ref><ref id="pone.0009462-Tran2"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tran</surname><given-names>CT</given-names></name><name><surname>Fox</surname><given-names>MF</given-names></name><name><surname>Vallance</surname><given-names>P</given-names></name><name><surname>Leiper</surname><given-names>JM</given-names></name></person-group><year>2000</year><article-title>Chromosomal localization, gene structure, and expression pattern of DDAH1: comparison with DDAH2 and implications for evolutionary origins.</article-title><source>Genomics</source><volume>68</volume><fpage>101</fpage><lpage>105</lpage><pub-id pub-id-type="pmid">10950934</pub-id></mixed-citation></ref><ref id="pone.0009462-Dayoub1"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dayoub</surname><given-names>H</given-names></name><name><surname>Achan</surname><given-names>V</given-names></name><name><surname>Adimoolam</surname><given-names>S</given-names></name><name><surname>Jacobi</surname><given-names>J</given-names></name><name><surname>Stuehlinger</surname><given-names>MC</given-names></name><etal/></person-group><year>2003</year><article-title>Dimethylarginine dimethylaminohydrolase regulates nitric oxide synthesis: genetic and physiological evidence.</article-title><source>Circulation</source><volume>108</volume><fpage>3042</fpage><lpage>3047</lpage><pub-id pub-id-type="pmid">14638548</pub-id></mixed-citation></ref><ref id="pone.0009462-WojciakStothard1"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wojciak-Stothard</surname><given-names>B</given-names></name><name><surname>Torondel</surname><given-names>B</given-names></name><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Renne</surname><given-names>T</given-names></name><name><surname>Leiper</surname><given-names>JM</given-names></name></person-group><year>2009</year><article-title>Modulation of Rac1 activity by ADMA/DDAH regulates pulmonary endothelial barrier function.</article-title><source>Mol Biol Cell</source><volume>20</volume><fpage>33</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">18923147</pub-id></mixed-citation></ref><ref id="pone.0009462-Duplain1"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duplain</surname><given-names>H</given-names></name><name><surname>Burcelin</surname><given-names>R</given-names></name><name><surname>Sartori</surname><given-names>C</given-names></name><name><surname>Cook</surname><given-names>S</given-names></name><name><surname>Egli</surname><given-names>M</given-names></name><etal/></person-group><year>2001</year><article-title>Insulin resistance, hyperlipidemia, and hypertension in mice lacking endothelial nitric oxide synthase.</article-title><source>Circulation</source><volume>104</volume><fpage>342</fpage><lpage>345</lpage><pub-id pub-id-type="pmid">11457755</pub-id></mixed-citation></ref><ref id="pone.0009462-Shankar1"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shankar</surname><given-names>RR</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Shen</surname><given-names>HQ</given-names></name><name><surname>Zhu</surname><given-names>JS</given-names></name><name><surname>Baron</surname><given-names>AD</given-names></name></person-group><year>2000</year><article-title>Mice with gene disruption of both endothelial and neuronal nitric oxide synthase exhibit insulin resistance.</article-title><source>Diabetes</source><volume>49</volume><fpage>684</fpage><lpage>687</lpage><pub-id pub-id-type="pmid">10905473</pub-id></mixed-citation></ref><ref id="pone.0009462-Stuhlinger1"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stuhlinger</surname><given-names>MC</given-names></name><name><surname>Abbasi</surname><given-names>F</given-names></name><name><surname>Chu</surname><given-names>JW</given-names></name><name><surname>Lamendola</surname><given-names>C</given-names></name><name><surname>McLaughlin</surname><given-names>TL</given-names></name><etal/></person-group><year>2002</year><article-title>Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor.</article-title><source>JAMA</source><volume>287</volume><fpage>1420</fpage><lpage>1426</lpage><pub-id pub-id-type="pmid">11903029</pub-id></mixed-citation></ref><ref id="pone.0009462-Sydow1"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sydow</surname><given-names>K</given-names></name><name><surname>Mondon</surname><given-names>CE</given-names></name><name><surname>Schrader</surname><given-names>J</given-names></name><name><surname>Konishi</surname><given-names>H</given-names></name><name><surname>Cooke</surname><given-names>JP</given-names></name></person-group><year>2008</year><article-title>Dimethylarginine dimethylaminohydrolase overexpression enhances insulin sensitivity.</article-title><source>Arterioscler Thromb Vasc Biol</source><volume>28</volume><fpage>692</fpage><lpage>697</lpage><pub-id pub-id-type="pmid">18239148</pub-id></mixed-citation></ref><ref id="pone.0009462-Lin1"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>KY</given-names></name><name><surname>Ito</surname><given-names>A</given-names></name><name><surname>Asagami</surname><given-names>T</given-names></name><name><surname>Tsao</surname><given-names>PS</given-names></name><name><surname>Adimoolam</surname><given-names>S</given-names></name><etal/></person-group><year>2002</year><article-title>Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase.</article-title><source>Circulation</source><volume>106</volume><fpage>987</fpage><lpage>992</lpage><pub-id pub-id-type="pmid">12186805</pub-id></mixed-citation></ref><ref id="pone.0009462-Forbes1"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forbes</surname><given-names>SP</given-names></name><name><surname>Druhan</surname><given-names>LJ</given-names></name><name><surname>Guzman</surname><given-names>JE</given-names></name><name><surname>Parinandi</surname><given-names>N</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><etal/></person-group><year>2008</year><article-title>Mechanism of 4-HNE mediated inhibition of hDDAH-1: implications in no regulation.</article-title><source>Biochemistry</source><volume>47</volume><fpage>1819</fpage><lpage>1826</lpage><pub-id pub-id-type="pmid">18171027</pub-id></mixed-citation></ref><ref id="pone.0009462-Ito1"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ito</surname><given-names>A</given-names></name><name><surname>Tsao</surname><given-names>PS</given-names></name><name><surname>Adimoolam</surname><given-names>S</given-names></name><name><surname>Kimoto</surname><given-names>M</given-names></name><name><surname>Ogawa</surname><given-names>T</given-names></name><etal/></person-group><year>1999</year><article-title>Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase.</article-title><source>Circulation</source><volume>99</volume><fpage>3092</fpage><lpage>3095</lpage><pub-id pub-id-type="pmid">10377069</pub-id></mixed-citation></ref><ref id="pone.0009462-MacAllister1"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacAllister</surname><given-names>RJ</given-names></name><name><surname>Parry</surname><given-names>H</given-names></name><name><surname>Kimoto</surname><given-names>M</given-names></name><name><surname>Ogawa</surname><given-names>T</given-names></name><name><surname>Russell</surname><given-names>RJ</given-names></name><etal/></person-group><year>1996</year><article-title>Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase.</article-title><source>Br J Pharmacol</source><volume>119</volume><fpage>1533</fpage><lpage>1540</lpage><pub-id pub-id-type="pmid">8982498</pub-id></mixed-citation></ref><ref id="pone.0009462-Jones1"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>LC</given-names></name><name><surname>Tran</surname><given-names>CT</given-names></name><name><surname>Leiper</surname><given-names>JM</given-names></name><name><surname>Hingorani</surname><given-names>AD</given-names></name><name><surname>Vallance</surname><given-names>P</given-names></name></person-group><year>2003</year><article-title>Common genetic variation in a basal promoter element alters DDAH2 expression in endothelial cells.</article-title><source>Biochem Biophys Res Commun</source><volume>310</volume><fpage>836</fpage><lpage>843</lpage><pub-id pub-id-type="pmid">14550280</pub-id></mixed-citation></ref><ref id="pone.0009462-Sakurada1"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakurada</surname><given-names>M</given-names></name><name><surname>Shichiri</surname><given-names>M</given-names></name><name><surname>Imamura</surname><given-names>M</given-names></name><name><surname>Azuma</surname><given-names>H</given-names></name><name><surname>Hirata</surname><given-names>Y</given-names></name></person-group><year>2008</year><article-title>Nitric oxide upregulates dimethylarginine dimethylaminohydrolase-2 via cyclic GMP induction in endothelial cells.</article-title><source>Hypertension</source><volume>52</volume><fpage>903</fpage><lpage>909</lpage><pub-id pub-id-type="pmid">18824664</pub-id></mixed-citation></ref><ref id="pone.0009462-Boger1"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boger</surname><given-names>RH</given-names></name><name><surname>Bode-Boger</surname><given-names>SM</given-names></name><name><surname>Szuba</surname><given-names>A</given-names></name><name><surname>Tsao</surname><given-names>PS</given-names></name><name><surname>Chan</surname><given-names>JR</given-names></name><etal/></person-group><year>1998</year><article-title>Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia.</article-title><source>Circulation</source><volume>98</volume><fpage>1842</fpage><lpage>1847</lpage><pub-id pub-id-type="pmid">9799202</pub-id></mixed-citation></ref><ref id="pone.0009462-Stuhlinger2"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stuhlinger</surname><given-names>MC</given-names></name><name><surname>Tsao</surname><given-names>PS</given-names></name><name><surname>Her</surname><given-names>JH</given-names></name><name><surname>Kimoto</surname><given-names>M</given-names></name><name><surname>Balint</surname><given-names>RF</given-names></name><etal/></person-group><year>2001</year><article-title>Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine.</article-title><source>Circulation</source><volume>104</volume><fpage>2569</fpage><lpage>2575</lpage><pub-id pub-id-type="pmid">11714652</pub-id></mixed-citation></ref><ref id="pone.0009462-Connell1"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Connell</surname><given-names>P</given-names></name><name><surname>Walshe</surname><given-names>T</given-names></name><name><surname>Ferguson</surname><given-names>G</given-names></name><name><surname>Gao</surname><given-names>W</given-names></name><name><surname>O'Brien</surname><given-names>C</given-names></name><etal/></person-group><year>2007</year><article-title>Elevated glucose attenuates agonist- and flow-stimulated endothelial nitric oxide synthase activity in microvascular retinal endothelial cells.</article-title><source>Endothelium</source><volume>14</volume><fpage>17</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">17364893</pub-id></mixed-citation></ref><ref id="pone.0009462-Carmo1"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carmo</surname><given-names>A</given-names></name><name><surname>Cunha-Vaz</surname><given-names>JG</given-names></name><name><surname>Carvalho</surname><given-names>AP</given-names></name><name><surname>Lopes</surname><given-names>MC</given-names></name></person-group><year>2000</year><article-title>Nitric oxide synthase activity in retinas from non-insulin-dependent diabetic Goto-Kakizaki rats: correlation with blood-retinal barrier permeability.</article-title><source>Nitric Oxide</source><volume>4</volume><fpage>590</fpage><lpage>596</lpage><pub-id pub-id-type="pmid">11139367</pub-id></mixed-citation></ref><ref id="pone.0009462-Yuan1"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>AH</given-names></name><name><surname>Mei</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>HY</given-names></name><name><surname>Xiang</surname><given-names>T</given-names></name><name><surname>Yang</surname><given-names>HJ</given-names></name></person-group><year>2007</year><article-title>&#x0005b;Expression pattern of nitric oxide synthase in the retina of diabetic rats&#x0005d;.</article-title><source>Nan Fang Yi Ke Da Xue Xue Bao</source><volume>27</volume><fpage>454</fpage><lpage>457</lpage><pub-id pub-id-type="pmid">17545029</pub-id></mixed-citation></ref><ref id="pone.0009462-AbuElAsrar1"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abu El-Asrar</surname><given-names>AM</given-names></name><name><surname>Desmet</surname><given-names>S</given-names></name><name><surname>Meersschaert</surname><given-names>A</given-names></name><name><surname>Dralands</surname><given-names>L</given-names></name><name><surname>Missotten</surname><given-names>L</given-names></name><etal/></person-group><year>2001</year><article-title>Expression of the inducible isoform of nitric oxide synthase in the retinas of human subjects with diabetes mellitus.</article-title><source>Am J Ophthalmol</source><volume>132</volume><fpage>551</fpage><lpage>556</lpage><pub-id pub-id-type="pmid">11589878</pub-id></mixed-citation></ref><ref id="pone.0009462-Tsai1"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsai</surname><given-names>DC</given-names></name><name><surname>Chiou</surname><given-names>SH</given-names></name><name><surname>Lee</surname><given-names>FL</given-names></name><name><surname>Chou</surname><given-names>CK</given-names></name><name><surname>Chen</surname><given-names>SJ</given-names></name><etal/></person-group><year>2003</year><article-title>Possible involvement of nitric oxide in the progression of diabetic retinopathy.</article-title><source>Ophthalmologica</source><volume>217</volume><fpage>342</fpage><lpage>346</lpage><pub-id pub-id-type="pmid">12913324</pub-id></mixed-citation></ref><ref id="pone.0009462-Ducharme1"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ducharme</surname><given-names>G</given-names></name><name><surname>Newell</surname><given-names>EW</given-names></name><name><surname>Pinto</surname><given-names>C</given-names></name><name><surname>Schlichter</surname><given-names>LC</given-names></name></person-group><year>2007</year><article-title>Small-conductance Cl&#x02212; channels contribute to volume regulation and phagocytosis in microglia.</article-title><source>Eur J Neurosci</source><volume>26</volume><fpage>2119</fpage><lpage>2130</lpage><pub-id pub-id-type="pmid">17927776</pub-id></mixed-citation></ref><ref id="pone.0009462-Fanucchi1"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fanucchi</surname><given-names>S</given-names></name><name><surname>Adamson</surname><given-names>RJ</given-names></name><name><surname>Dirr</surname><given-names>HW</given-names></name></person-group><year>2008</year><article-title>Formation of an unfolding intermediate state of soluble chloride intracellular channel protein CLIC1 at acidic pH.</article-title><source>Biochemistry</source><volume>47</volume><fpage>11674</fpage><lpage>11681</lpage><pub-id pub-id-type="pmid">18850721</pub-id></mixed-citation></ref><ref id="pone.0009462-Valenzuela1"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valenzuela</surname><given-names>SM</given-names></name><name><surname>Mazzanti</surname><given-names>M</given-names></name><name><surname>Tonini</surname><given-names>R</given-names></name><name><surname>Qiu</surname><given-names>MR</given-names></name><name><surname>Warton</surname><given-names>K</given-names></name><etal/></person-group><year>2000</year><article-title>The nuclear chloride ion channel NCC27 is involved in regulation of the cell cycle.</article-title><source>J Physiol</source><volume>529 Pt 3</volume><fpage>541</fpage><lpage>552</lpage><pub-id pub-id-type="pmid">11195932</pub-id></mixed-citation></ref><ref id="pone.0009462-1"><label>39</label><mixed-citation publication-type="journal"><year>1991</year><article-title>Grading diabetic retinopathy from stereoscopic color fundus photographs&#x02013;an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group.</article-title><source>Ophthalmology</source><volume>98</volume><fpage>786</fpage><lpage>806</lpage><pub-id pub-id-type="pmid">2062513</pub-id></mixed-citation></ref><ref id="pone.0009462-Barrett1"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barrett</surname><given-names>JC</given-names></name><name><surname>Fry</surname><given-names>B</given-names></name><name><surname>Maller</surname><given-names>J</given-names></name><name><surname>Daly</surname><given-names>MJ</given-names></name></person-group><year>2005</year><article-title>Haploview: analysis and visualization of LD and haplotype maps.</article-title><source>Bioinformatics</source><volume>21</volume><fpage>263</fpage><lpage>265</lpage><pub-id pub-id-type="pmid">15297300</pub-id></mixed-citation></ref><ref id="pone.0009462-2"><label>41</label><mixed-citation publication-type="journal"><year>2003</year><article-title>The International HapMap Project.</article-title><source>Nature</source><volume>426</volume><fpage>789</fpage><lpage>796</lpage><pub-id pub-id-type="pmid">14685227</pub-id></mixed-citation></ref><ref id="pone.0009462-Schwedhelm1"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwedhelm</surname><given-names>E</given-names></name><name><surname>Tan-Andresen</surname><given-names>J</given-names></name><name><surname>Maas</surname><given-names>R</given-names></name><name><surname>Riederer</surname><given-names>U</given-names></name><name><surname>Schulze</surname><given-names>F</given-names></name><etal/></person-group><year>2005</year><article-title>Liquid chromatography-tandem mass spectrometry method for the analysis of asymmetric dimethylarginine in human plasma.</article-title><source>Clin Chem</source><volume>51</volume><fpage>1268</fpage><lpage>1271</lpage><pub-id pub-id-type="pmid">15976109</pub-id></mixed-citation></ref><ref id="pone.0009462-Purcell1"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Purcell</surname><given-names>S</given-names></name><name><surname>Neale</surname><given-names>B</given-names></name><name><surname>Todd-Brown</surname><given-names>K</given-names></name><name><surname>Thomas</surname><given-names>L</given-names></name><name><surname>Ferreira</surname><given-names>MA</given-names></name><etal/></person-group><year>2007</year><article-title>PLINK: a tool set for whole-genome association and population-based linkage analyses.</article-title><source>Am J Hum Genet</source><volume>81</volume><fpage>559</fpage><lpage>575</lpage><pub-id pub-id-type="pmid">17701901</pub-id></mixed-citation></ref><ref id="pone.0009462-Nyholt1"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nyholt</surname><given-names>DR</given-names></name></person-group><year>2004</year><article-title>A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other.</article-title><source>Am J Hum Genet</source><volume>74</volume><fpage>765</fpage><lpage>769</lpage><pub-id pub-id-type="pmid">14997420</pub-id></mixed-citation></ref><ref id="pone.0009462-Li1"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Ji</surname><given-names>L</given-names></name></person-group><year>2005</year><article-title>Adjusting multiple testing in multilocus analyses using the eigenvalues of a correlation matrix.</article-title><source>Heredity</source><volume>95</volume><fpage>221</fpage><lpage>227</lpage><pub-id pub-id-type="pmid">16077740</pub-id></mixed-citation></ref></ref-list><fn-group><fn fn-type="conflict"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding: </bold>This research was supported by a grant from the Ophthalmic Research Institute of Australia. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></fn></fn-group></back></article>